SCHEMBL1099987

SCHEMBL1099987

Cc1c(N(CCC2CC2)S(=O)(=O)c2cnccc2N2CCOCC2)sc2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 7/20 0.37
CA1 P00915 7/20 0.37
CA2 P00918 7/20 0.37
CA9 Q16790 7/20 0.37
LMNA P02545 1/20 0.35
TRPM8 Q7Z2W7 2/20 0.35
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PIK3CD O00329 1/20 0.34
ALDH1A1 P00352 2/20 0.33
POLB P06746 2/20 0.33
PKM P14618 1/20 0.33
OPRL1 P41146 1/20 0.32
CYP3A4 P08684 1/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32
DRD3 P35462 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099543 0.86 LMNA (0.34) CA12CA1CA2CA9LMNA
SCHEMBL1100358 0.82 TRPM8 (0.41) TRPM8ALDH1A1PKMHTR1AHTR2A
SCHEMBL1097559 0.82 TRPM8 (0.34) TRPM8HTR1ADRD2HTR2ADRD3
SCHEMBL1099989 0.81 CYP2C9 (0.38) CA12CA1CA2CA9LMNA
SCHEMBL1099801 0.81 TRPM8 (0.55) TRPM8
SCHEMBL1099078 0.78 TRPM8 (0.32) TRPM8
SCHEMBL1098474 0.76 TRPM8 (0.33) TRPM8
SCHEMBL1098232 0.74 TRPM8 (0.48) LMNATRPM8ALDH1A1HTR2AMEN1
SCHEMBL1099902 0.74 CNR2 (0.46) TRPM8HTR1ADRD2HTR2ADRD3
SCHEMBL1098150 0.73 TRPM8 (0.41) TRPM8HTR1ADRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CA12 2056/4885CA1 1538/4885CA2 264/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CA12 2056/4885CA1 1538/4885CA2 264/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CA12 2056/4885CA1 1538/4885CA2 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.